In a phase 3 double-blind, randomized trial, patients with COPD and high blood eosinophil counts were assigned either dupilumab or placebo. Dupilumab showed significant benefits compared to placebo, including reduced exacerbations, improved lung function, better quality of life, and less severe respiratory symptoms. These positive effects were maintained even after 52 weeks.

Image courtesy of interviewee